Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
2016 · New England Journal of Medicine · 1,327 citations
https://doi.org/10.1056/nejmoa1509277
A
Anjali S. Advani
Cleveland Clinic(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
620
Papers
13.7K
Citations
56
h-index
183
i10-index
Anjali S. Advani is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Acute Lymphoblastic Leukemia research & Chronic Myeloid Leukemia Treatments. The author has an h-index of 56, co-authored 527 publications.
ORCID: 0000-0003-0015-5902Papers by this author
worksA pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
2019 · Blood · 454 citations
https://doi.org/10.1182/blood-2018-10-881961
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
2019 · Cancer · 316 citations
https://doi.org/10.1002/cncr.32116
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
2024 · New England Journal of Medicine · 183 citations
https://doi.org/10.1056/nejmoa2312948
Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia
2018 · JAMA Oncology · 161 citations
https://doi.org/10.1001/jamaoncol.2017.5305
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
2017 · Blood Advances · 130 citations
https://doi.org/10.1182/bloodadvances.2016001925
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat